Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Penumbra reports strong Q3 earnings, eyes global blood clot market

Penumbra's Q3 2024 earnings call showcased robust financial performance, driven by revenue growth and margin expansion. The company's innovative technologies and regulatory milestones position it for future success in the blood clot treatment market. While facing challenges in sustaining growth and navigating market dynamics, Penumbra has opportunities to capitalize on its strengths and drive global transformation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

NEW YORK--(BUSINESS WIRE)--Nationally ranked litigation firm Labaton Sucharow announces investigation of Penumbra, Inc. ("Penumbra" Or The "Company") (NYSE: PEN) and encourages investors with losses to contact the Firm. Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The investigation focuses on whether Penumbra issued false and/or misleading statements and/or failed to disclose information

STOCK ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of Penumbra, Inc. ("Penumbra" Or The "Company") (NYSE: PEN) and Encourages Investors With Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $PEN #PEN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Penumbra, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Penumbra, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading business information to the investing public. On November 10, 2020, Quintessential Capital Management released research report on the Company entitled “Penumbra and its ‘Killer Catheter': A tale of corporate greed and seemingly

ROSEN, A TOP RANKED LAW FIRM, Commences Investigation of Securities Claims Against Penumbra, Inc. Seeking Recovery of Investor Losses; Encourages Investors with Losses Over $100K to Seek Counsel – PEN

LOS ANGELES--(BUSINESS WIRE)---- $PEN #PEN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Penumbra, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Penumbra, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Penumbra's stock was tanking after short-seller Quintessential Capital put out another critical report.

Shares of medical device maker Penumbra tank after short seller releases critical report

Investors can contact the law firm at no cost to learn more about recovering their losses

Penumbra Investors: Company Investigated by the Portnoy Law Firm

Investors are rattled by a short-seller's report.

Why Penumbra Stock Is Plunging Today

ALAMEDA, Calif., Dec. 4, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020. Event: CEO Discussion with Bank of America Date: Tuesday, December 8,...

Penumbra, Inc. to Participate in CEO Discussion with Bank of America

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #aspiration--Penumbra's Indigo Aspiration System Lightning 12 received FDA clearance for the treatment of pulmonary embolism.

Penumbra's Newest Generation of Indigo Aspiration System Receives FDA Clearance for Pulmonary Embolism

Shares in healthcare device manufacturer Penumbra fell by as much as 8% on Tuesday, after activist short seller Gabriel Grego said he had added the stock to his sell-list.  Grego announced the new short position while appearing on investor Carson Block's new short-selling show 'The Chopping Block".

Penumbra falls as much as 8% after short activist hedge fund manager Gabriel Grego says sell the stock

ALAMEDA, Calif., Nov. 10, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced a new partnership to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures...

Penumbra Announces Partnership with RapidAI to Enable Faster Clinical Decision-Making for Pulmonary Embolism

ALAMEDA, Calif., Nov. 6, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. Event: Canaccord Genuity Virtual MedTech & Diagnostics...

Penumbra, Inc. to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

The healthcare company posted better-than-expected Q3 results.

Why Penumbra Stock Is Popping Today

Penumbra, Inc.'s (PEN) CEO Adam Elsesser on Q3 2020 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of 146.15% and 20.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Q3 Earnings and Revenues Surpass Estimates

Boston Scientific

Cerner

Livongo Health Inc

In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.

Medical Products Q3 Earnings on Oct 28: BSX, CERN & More

ALAMEDA, Calif., Aug. 26, 2020 /PRNewswire/ -- Penumbra, Inc.

Penumbra, Inc. to Present at the Wells Fargo 2020 Virtual Healthcare Conference

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q2 2020 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of 37.50% and 6.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Reports Q2 Loss, Tops Revenue Estimates

Shares of Penumbra (NYSE:PEN) fell 0.25% after the company reported Q2 results. Quarterly Results Earnings per share fell 211.11% year over year to ($0.30), which beat the estimate of ($0.39).

Penumbra: Q2 Earnings Insights

ALAMEDA, Calif., Aug. 3, 2020 /PRNewswire/ -- Penumbra, Inc.

Penumbra, Inc. Reports Second Quarter 2020 Financial Results

ALAMEDA, Calif., July 29, 2020 /PRNewswire/ -- Penumbra, Inc.

Penumbra, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Penumbra (PEN) Q2 Earnings Expected to Decline

A Relative Strength Rating upgrade for Penumbra shows improving technical performance.

Penumbra Earns Relative Strength Rating Upgrade; Hits Key Benchmark

ALAMEDA, Calif., May 29, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, 2020. Event: William Blair 40th Annual Growth Stock Conference Date:...

News for Penumbra Stock (PEN)